Vidaza Disease Interactions

The use of azacitidine injection is contraindicated in patients with advanced malignant hepatic tumors.

Azacitidine is potentially hepatotoxic in patients with preexisting hepatic impairment and caution should be exercised when prescribing in patients with liver disease.

Patients with renal impairment may be at increased risk of renal toxicity when using azacitidine. This drug is primarily excreted by the kidneys. Therefore, these patients should be closely monitored for toxicity.

Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.